Deal Ends Today·Save 35% annual plan
RANK ligand inhibitor (bone-loss agent)Reviewed for 2026 plan year

Does Aetna Cover Prolia?

The verdict

Covered on most plans

Aetna (CVS Health) covers Prolia under the medical benefit with prior authorization, administered as a q6-month clinic injection. Aetna's CVS Health integration is the defining feature: CVS Caremark is the PBM and CVS Specialty the specialty pharmacy for the pharmacy-benefit pathway where it applies, and CVS has been aggressive on biosimilar substitution (as demonstrated with Humira). The same posture is emerging for denosumab — Jubbonti biosimilar preference is increasing. For most members, however, Prolia runs through the medical benefit as a buy-and-bill office injection, not a pharmacy drug. Not covered outside FDA-approved osteoporosis indications.

MedicareCovered
CommercialCovered
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Aetna using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Aetna drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Prolia is most often a medical-benefit buy-and-bill drug administered in the clinic every 6 months — billed under HCPCS J0897 per CMS Local Coverage Determination L33394 — not a Part D pharmacy pickup. The $2,100 Part D OOP cap does not apply.

    CMS Local Coverage Determination L33394; Medicare.gov

  • CVS Health (Aetna's parent) removed branded Humira from its major commercial formularies in April 2024, substituting biosimilars — the same aggressive biosimilar-substitution posture is now emerging for denosumab (Jubbonti biosimilar preference).

    CVS Health announcement Jan. 3, 2024; Amgen Jubbonti prescribing information

  • Original Medicare Part B covers 80% of Prolia's approved cost; the member's 20% coinsurance is approximately $357 per injection at average pricing — a Medigap supplement typically covers this 20%.

    Medicare.org Part B drug cost estimates, 2025

Plan types

Medicare vs. commercial coverage

Whether Aetna covers Prolia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Covered

Medicare (medical benefit — operative pathway for most Aetna Medicare members): Prolia is administered in-office as a subcutaneous injection every 6 months and billed under HCPCS code J0897, incident to a physician service per Local Coverage Determination L33394. Original Medicare (with an Aetna Medicare supplement) covers 80% after the Part B deductible; the member pays 20% coinsurance — approximately $357 per injection at average pricing (Medicare.org). Aetna Medicare Advantage plans may require prior authorization and increasingly prefer the interchangeable Jubbonti biosimilar (denosumab-bddz) following the broader market trend. Observed MA copays range $0–$500 per injection depending on plan design — verify on your specific Aetna MA plan. The $2,100 Part D OOP cap does NOT apply to Part B drugs — this is a critical distinction.

Commercial / Employer

Group & marketplace plans

Covered

Commercial/Employer: Prolia is covered under the medical benefit with prior authorization; documentation of osteoporosis with high fracture risk (T-score at or below -2.5, prior fragility fracture, or high FRAX) is required. PA approval is typically 12 months. When the pharmacy benefit pathway applies (e.g., certain plan designs), CVS Caremark manages the formulary and CVS Specialty handles dispensing — and CVS has shown a strong biosimilar-substitution posture (Humira biosimilar switch April 2024). Biosimilar Jubbonti emerging as preferred on CVS Caremark. ACA/Individual: covered with PA where offered. Medicaid: Aetna-managed Medicaid covers Prolia for osteoporosis with high fracture risk per state PDL; nominal cost-share. Not covered outside approved indications.

Prior authorization

The 3 boxes you must tick to get approved

Commercial plans that will consider Prolia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 3

Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Prolia actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Cash price approximately $1,786–$2,507 per 60 mg denosumab dose without insurance (sources vary: Medicare.org approximately $1,786; GoodRx approximately $2,507). These are estimates — actual cash price varies by site of care.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Medical benefit pathway: Medicare Part B 20% coinsurance after Part B deductible — approximately $357 per injection at average pricing (Medicare.org, 2025 deductible applied); Medigap covers the 20%, often resulting in $0. Aetna Medicare Advantage: observed copays $0–$500 per injection depending on plan design — verify on your specific Aetna MA plan. Commercial medical benefit: coinsurance per plan design; varies. Medicaid: nominal cost-share per state PDL.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

Amgen offers copay support for Prolia (commercially insured patients only). Medicare and Medicaid beneficiaries are NOT eligible for manufacturer copay assistance under federal anti-kickback rules. CVS Specialty will handle dispensing if routed through the pharmacy benefit — contact CVS Specialty for additional assistance program information.

Reduced copay through the assistance program, where eligible.

All figures are estimates. The Part D $2,100 OOP cap does NOT apply to the Part B medical pathway — Prolia is a Part B drug for most Aetna members. Verify your specific cost-share with Aetna member services or your MA plan documents.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Confirm your Prolia coverage runs through the medical benefit at Aetna

    For most Aetna Medicare and commercial members, Prolia is a medical-benefit drug administered in the doctor's office every 6 months — not a Part D pharmacy pickup. Log in to your Aetna member account at aetna.com or call Aetna member services to verify your specific plan's benefit structure. Check the medical benefit (Part B) section for denosumab, not the drug formulary. If your Aetna commercial plan routes Prolia through CVS Caremark, you can also check the CVS Caremark formulary at caremark.com.

  2. 2

    Ask your prescriber to initiate prior authorization through Aetna's medical policy

    Your prescribing clinician (primary care physician, OB/GYN, endocrinologist) submits the PA to Aetna. Include documentation of osteoporosis with high fracture risk: DEXA scan results (T-score), prior fracture history, or FRAX score. Aetna's PA process for the medical benefit pathway differs from the pharmacy-benefit PA process — your prescriber should specify the medical-benefit pathway (HCPCS J0897, administered in-office). PA approval is typically 12 months.

  3. 3

    Check for Jubbonti biosimilar preference if routing through CVS Caremark

    If your Aetna plan routes denosumab through the pharmacy benefit (CVS Caremark), verify whether Jubbonti (denosumab-bddz) is the current preferred product on the CVS Caremark formulary. CVS has been aggressive on biosimilar substitution — the same posture it showed with Humira (April 2024) is emerging for denosumab. Jubbonti is FDA-approved as an interchangeable biosimilar for Prolia: same molecule (denosumab), same 60 mg dose, same q6-month schedule.

If it's denied

Options if Aetna won't cover Prolia

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Jubbonti (denosumab-bddz)

FDA-approved interchangeable biosimilar for Prolia. Emerging as preferred over branded Prolia on CVS Caremark formularies consistent with market trends. Same molecule (denosumab), same 60 mg subcutaneous dose, same q6-month administration schedule. Verify current preferred status on CVS Caremark formulary.

Fosamax (alendronate) — generic

Oral bisphosphonate, generic, Tier 1 on most formularies. First-line osteoporosis treatment; often considered before injectable agents. May be required as prior treatment documentation for some PA criteria.

Reclast (zoledronic acid)

Annual IV bisphosphonate infusion administered in-office. Medical benefit drug at lower cost than Prolia. Option for patients unable to tolerate oral bisphosphonates.

Forteo (teriparatide) / generic teriparatide

Anabolic bone agent, self-injected daily under the pharmacy benefit. A fundamentally different drug class (PTH analog), benefit rail (pharmacy vs. medical), and dosing schedule. Brand Forteo is often excluded by Aetna/CVS Caremark in favor of generic teriparatide or Bonsity — in contrast to Prolia, which is cleanly covered on the medical benefit.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

For most Aetna members, Prolia is covered under the medical benefit — it is a clinician-administered subcutaneous injection given in-office every 6 months, billed under HCPCS J0897 per CMS Local Coverage Determination L33394. This is not a pharmacy-counter drug. The $2,100 Part D out-of-pocket cap does not apply to the medical benefit pathway. Where Aetna routes denosumab through the pharmacy benefit, CVS Caremark and CVS Specialty manage that pathway.

Jubbonti (denosumab-bddz) is the FDA-approved interchangeable biosimilar for Prolia, and CVS Health has demonstrated a strong biosimilar-substitution posture across its business (removing branded Humira from formularies in April 2024). Jubbonti biosimilar preference is emerging on CVS Caremark formularies. If your Aetna plan routes denosumab through the CVS Caremark pharmacy benefit, verify whether Jubbonti is now the preferred product on your current plan formulary.

On the medical benefit with original Medicare plus Aetna supplement, you pay 20% coinsurance after the Part B deductible — approximately $357 per injection at average pricing. A Medigap plan typically covers this 20%. On Aetna Medicare Advantage, copays range $0–$500 per injection depending on plan design — verify on your specific plan. On commercial: medical-benefit coinsurance per plan. All figures are estimates; verify your specific cost-share with Aetna or CVS Caremark.

No — not on the medical benefit pathway. For most Aetna Medicare members, Prolia is a Part B medical-benefit drug, not a Part D pharmacy drug. The $2,100 (2026) Part D OOP cap applies only to Part D drugs. Your Part B cost-share is governed by the Part B coinsurance structure and your supplemental coverage (Medigap or Aetna MA plan). This is one of the most important distinctions when comparing Prolia to Part D specialty drugs.

Only if you have Aetna commercial insurance — not Medicare or Medicaid. Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer copay assistance programs. Commercially insured Aetna members may be eligible for Amgen's Prolia copay support — verify directly with Amgen. If your denosumab routes through CVS Specialty, ask CVS Specialty about any available assistance programs at the time of fill.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Aetna before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.